Compare Amplify Transformational Data Sharing ETF (BLOK) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs IDEXX Laboratories, Inc. — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.55, while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| BLOK | IDXX | |
|---|---|---|
52-Week High | $74.10 | $766.68 |
52-Week Low | $47.36 | $526.44 |
Market Cap | — | $46.22B |
Sector | — | Health |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.00, up 1.56% today, but faces bearish technical signals with 14 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal downward pressure. Recent institutional activity shows Dynamic Advisor Solutions reduced its position by 81.1% in Q2 2026. The ETF focuses on transformational data sharing companies with exposure to AI infrastructure and blockchain economy participants.
The outlook remains cautious given bearish technical indicators and institutional selling. Investment opportunity exists in the ETF's diversified exposure to data sharing and AI infrastructure growth, but risks include sector volatility and competitive ETF pressure. The dividend of $0.08 scheduled for June 2026 provides minor income support amid uncertain market conditions.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
